AU2014213795B2 - Combination therapy for the treatment of nosocomial pneumonia - Google Patents

Combination therapy for the treatment of nosocomial pneumonia Download PDF

Info

Publication number
AU2014213795B2
AU2014213795B2 AU2014213795A AU2014213795A AU2014213795B2 AU 2014213795 B2 AU2014213795 B2 AU 2014213795B2 AU 2014213795 A AU2014213795 A AU 2014213795A AU 2014213795 A AU2014213795 A AU 2014213795A AU 2014213795 B2 AU2014213795 B2 AU 2014213795B2
Authority
AU
Australia
Prior art keywords
ceftazidime
avibactam
combination
mice
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014213795A
Other languages
English (en)
Other versions
AU2014213795A1 (en
Inventor
Shampa DAS
Jianguo Li
Johan Willem Mouton
Wright NICHOLS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Anti Infectives AB
Original Assignee
Pfizer Anti Infectives AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50114393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014213795(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Anti Infectives AB filed Critical Pfizer Anti Infectives AB
Publication of AU2014213795A1 publication Critical patent/AU2014213795A1/en
Application granted granted Critical
Publication of AU2014213795B2 publication Critical patent/AU2014213795B2/en
Assigned to PFIZER ANTI-INFECTIVES AB reassignment PFIZER ANTI-INFECTIVES AB Request to Amend Deed and Register Assignors: ASTRAZENECA AB
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014213795A 2013-02-06 2014-02-06 Combination therapy for the treatment of nosocomial pneumonia Active AU2014213795B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361761369P 2013-02-06 2013-02-06
US61/761,369 2013-02-06
PCT/GB2014/050354 WO2014122468A1 (en) 2013-02-06 2014-02-06 Combination therapy for the treatment of nosocomial pneumonia

Publications (2)

Publication Number Publication Date
AU2014213795A1 AU2014213795A1 (en) 2015-07-30
AU2014213795B2 true AU2014213795B2 (en) 2016-10-13

Family

ID=50114393

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014213795A Active AU2014213795B2 (en) 2013-02-06 2014-02-06 Combination therapy for the treatment of nosocomial pneumonia

Country Status (13)

Country Link
US (1) US20150374673A1 (OSRAM)
EP (1) EP2953626A1 (OSRAM)
JP (1) JP6383367B2 (OSRAM)
KR (1) KR20150115761A (OSRAM)
CN (2) CN104994860A (OSRAM)
AU (1) AU2014213795B2 (OSRAM)
BR (1) BR112015018360B1 (OSRAM)
CA (1) CA2897446A1 (OSRAM)
CL (1) CL2015002180A1 (OSRAM)
MX (1) MX2015010077A (OSRAM)
RU (1) RU2684112C2 (OSRAM)
UA (1) UA115683C2 (OSRAM)
WO (1) WO2014122468A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017010132B1 (pt) 2014-11-17 2023-02-14 Entasis Therapeutics Limited Combinações e seus usos no tratamento de infecções bacterianas resistentes
WO2016156344A1 (en) 2015-03-31 2016-10-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
JP2018515481A (ja) 2015-09-16 2018-06-14 シュアンチュー ファーマ カンパニー，リミティド β−ラクタマーゼ阻害剤とその利用
MX2018014813A (es) * 2016-06-17 2019-03-14 Wockhardt Ltd Composiciones antibacterianas.
CA3036557A1 (en) 2016-09-16 2018-03-22 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
PL3630111T3 (pl) 2017-05-08 2022-05-23 Entasis Therapeutics, Inc. Związki i sposoby leczenia zakażeń bakteryjnych
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
KR102790878B1 (ko) 2018-08-09 2025-04-02 앤타바이오 에스에이에스 세린 베타-락타마제의 억제제로서 다이아자바이사이클로옥타논
RU2746833C1 (ru) * 2020-08-03 2021-04-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ моделирования экспериментального воспаления легких у крыс
CN113413367B (zh) * 2021-08-16 2026-03-20 浙江尖峰药业有限公司 一种注射用阿维巴坦头孢甲肟复方粉针及其制备方法
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
CN119818504A (zh) * 2025-01-04 2025-04-15 重庆圣华曦药业股份有限公司 一种头孢哌酮和阿维巴坦的抗菌组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101076342A (zh) * 2004-12-17 2007-11-21 维纳斯药业有限公司 用于对治疗感染提供总解决方案的抗生素组合
CN101074235B (zh) * 2006-05-15 2010-05-12 中国药品生物制品检定所 头孢硫脒醇水化合物及其制备方法
CN101245080A (zh) * 2007-02-14 2008-08-20 山东轩竹医药科技有限公司 含有吡唑并三唑的头孢菌素衍生物
EP2410985A2 (en) * 2009-03-26 2012-02-01 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BONNEFOY, A. et al., Journal of Antimicrobial Chemotherapy. 2004, vol. 54, no. 2, pages 410-417 *
BRESSOLLE, F. et al., Antimicrobial Agents and Chemotherapy. 1992, vol. 36, no. 7, pages 1404-1411 *
DRAWZ, S. M. et al., Clinical Microbiology Reviews. 2010, vol. 23, no. 1, pages 160-201 *
LEVASSEUR, P. et al., Antimicrobial Agents And Chemotherapy. 2012, vol. 56, no. 3, pages 1606-1608 *
LEVASSEUR, P. et al.,46th Interscience Conference On Antimicrobial Agents & Chemotherapy (ICAAC), San Francisco. 2006,<URL: http://www.microbiotix.com/posters/ICAAC-2006/POSTERS%20BY%20OTHERS/ICAAC_2006_NXL_104_Levasseur_Poster_F-127.pdf] *
LORENTE, L. et al., Clinical Therapeutics. 2007, vol. 29, no. 11, pages 2433-2439 *

Also Published As

Publication number Publication date
AU2014213795A1 (en) 2015-07-30
JP6383367B2 (ja) 2018-08-29
WO2014122468A1 (en) 2014-08-14
CN104994860A (zh) 2015-10-21
UA115683C2 (uk) 2017-12-11
BR112015018360B1 (pt) 2022-03-22
CA2897446A1 (en) 2014-08-14
MX2015010077A (es) 2016-01-25
CL2015002180A1 (es) 2015-11-27
US20150374673A1 (en) 2015-12-31
KR20150115761A (ko) 2015-10-14
EP2953626A1 (en) 2015-12-16
CN110302203A (zh) 2019-10-08
JP2016507547A (ja) 2016-03-10
RU2015132369A (ru) 2017-03-13
BR112015018360A2 (pt) 2017-07-18
RU2684112C2 (ru) 2019-04-04

Similar Documents

Publication Publication Date Title
US20150374673A1 (en) Combination Therapy for the Treatment of Nosocomial Pneumonia
US10376499B2 (en) Combination therapy for treatment of resistant bacterial infections
EP3003307B1 (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
HK1244798A1 (en) Combination therapy for treatment of resistant bacterial infections
WO2014144295A1 (en) Ceftolozane antibiotic compositions
RU2524665C2 (ru) Композиции и способы лечения, включающие цефтаролин
Lewis et al. Antibacterial agents
WO2017203266A1 (en) Combination therapy for treatment of resistant bacterial infections
EP2600868B1 (en) Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent
Zander et al. Antimicrobial activities of trimethoprim/sulfamethoxazole, 5-iodo-2′-deoxyuridine and rifampicin against Staphylococcus aureus
US11129840B2 (en) Methods for identifying novel dosing regimens
Vivas et al. Effect of dexamethasone on the efficacy of daptomycin in the therapy of experimental pneumococcal meningitis
HK40012654A (en) Combination therapy for the treatment of nosocomial pneumonia
HK1223305B (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
EP3294317A1 (en) Enhanced antibiotic composition
HK1183615B (en) Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent
HK1183615A (en) Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: PFIZER ANTI-INFECTIVES AB

Free format text: FORMER NAME(S): ASTRAZENECA AB